Skeletal muscle vulnerability in a child with Pitt-Hopkins syndrome.
Muscle
Muscle proteomics
Myogenesis
Pitt Hopkins syndrome
TCF4
Journal
Skeletal muscle
ISSN: 2044-5040
Titre abrégé: Skelet Muscle
Pays: England
ID NLM: 101561193
Informations de publication
Date de publication:
18 Jul 2024
18 Jul 2024
Historique:
received:
14
12
2023
accepted:
29
06
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
18
7
2024
Statut:
epublish
Résumé
TCF4 acts as a transcription factor that binds to the immunoglobulin enhancer Mu-E5/KE5 motif. Dominant variants in TCF4 are associated with the manifestation of Pitt-Hopkins syndrome, a rare disease characterized by severe mental retardation, certain features of facial dysmorphism and, in many cases, with abnormalities in respiratory rhythm (episodes of paroxysmal tachypnea and hyperventilation, followed by apnea and cyanosis). Frequently, patients also develop epilepsy, microcephaly, and postnatal short stature. Although TCF4 is expressed in skeletal muscle and TCF4 seems to play a role in myogenesis as demonstrated in mice, potential myopathological findings taking place upon the presence of dominant TCF4 variants are thus far not described in human skeletal muscle. To address the pathological effect of a novel deletion affecting exons 15 and 16 of TCF4 on skeletal muscle, histological and immunofluorescence studies were carried out on a quadriceps biopsy in addition to targeted transcript studies and global proteomic profiling. We report on muscle biopsy findings from a Pitt-Hopkins patient with a novel heterozygous deletion spanning exon 15 and 16 presenting with neuromuscular symptoms. Microscopic characterization of the muscle biopsy revealed moderate fiber type I predominance, imbalance in the proportion of fibroblasts co-expressing Vimentin and CD90, and indicate activation of the complement cascade in TCF4-mutant muscle. Protein dysregulations were unraveled by proteomic profiling. Transcript studies confirmed a mitochondrial vulnerability in muscle and confirmed reduced TCF4 expression. Our combined findings, for the first time, unveil myopathological changes as phenotypical association of Pitt-Hopkins syndrome and thus expand the current clinical knowledge of the disease as well as support data obtained on skeletal muscle of a mouse model.
Sections du résumé
BACKGROUND
BACKGROUND
TCF4 acts as a transcription factor that binds to the immunoglobulin enhancer Mu-E5/KE5 motif. Dominant variants in TCF4 are associated with the manifestation of Pitt-Hopkins syndrome, a rare disease characterized by severe mental retardation, certain features of facial dysmorphism and, in many cases, with abnormalities in respiratory rhythm (episodes of paroxysmal tachypnea and hyperventilation, followed by apnea and cyanosis). Frequently, patients also develop epilepsy, microcephaly, and postnatal short stature. Although TCF4 is expressed in skeletal muscle and TCF4 seems to play a role in myogenesis as demonstrated in mice, potential myopathological findings taking place upon the presence of dominant TCF4 variants are thus far not described in human skeletal muscle.
METHOD
METHODS
To address the pathological effect of a novel deletion affecting exons 15 and 16 of TCF4 on skeletal muscle, histological and immunofluorescence studies were carried out on a quadriceps biopsy in addition to targeted transcript studies and global proteomic profiling.
RESULTS
RESULTS
We report on muscle biopsy findings from a Pitt-Hopkins patient with a novel heterozygous deletion spanning exon 15 and 16 presenting with neuromuscular symptoms. Microscopic characterization of the muscle biopsy revealed moderate fiber type I predominance, imbalance in the proportion of fibroblasts co-expressing Vimentin and CD90, and indicate activation of the complement cascade in TCF4-mutant muscle. Protein dysregulations were unraveled by proteomic profiling. Transcript studies confirmed a mitochondrial vulnerability in muscle and confirmed reduced TCF4 expression.
CONCLUSION
CONCLUSIONS
Our combined findings, for the first time, unveil myopathological changes as phenotypical association of Pitt-Hopkins syndrome and thus expand the current clinical knowledge of the disease as well as support data obtained on skeletal muscle of a mouse model.
Identifiants
pubmed: 39026379
doi: 10.1186/s13395-024-00348-0
pii: 10.1186/s13395-024-00348-0
doi:
Substances chimiques
Transcription Factor 4
0
TCF4 protein, human
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Informations de copyright
© 2024. The Author(s).
Références
Forrest MP, Hill MJ, Quantock AJ, Martin-Rendon E, Blake DJ. The emerging roles of TCF4 in disease and development. Trends Mol Med. 2014;20(6):322–31.
doi: 10.1016/j.molmed.2014.01.010
pubmed: 24594265
Flora A, Garcia JJ, Thaller C, Zoghbi HY. The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc Natl Acad Sci U S A. 2007;104(39):15382–7.
doi: 10.1073/pnas.0707456104
pubmed: 17878293
pmcid: 1978485
Skerjanc IS, Truong J, Filion P, McBurney MW. A splice variant of the ITF-2 transcript encodes a transcription factor that inhibits MyoD activity. J Biol Chem. 1996;271(7):3555–61.
doi: 10.1074/jbc.271.7.3555
pubmed: 8631961
de Pontual L, Mathieu Y, Golzio C, Rio M, Malan V, Boddaert N, Soufflet C, Picard C, Durandy A, Dobbie A, et al. Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndrome. Hum Mutat. 2009;30(4):669–76.
doi: 10.1002/humu.20935
pubmed: 19235238
Chen B, Lim RW. Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b. Evidence toward a novel mechanism regulating muscle-specific gene expression. J Biol Chem. 1997;272(4):2459–63.
doi: 10.1074/jbc.272.4.2459
pubmed: 8999959
Kardon G, Harfe BD, Tabin CJ. A Tcf4-positive mesodermal population provides a prepattern for vertebrate limb muscle patterning. Dev Cell. 2003;5(6):937–44.
doi: 10.1016/S1534-5807(03)00360-5
pubmed: 14667415
Amiel J, Rio M, de Pontual L, Redon R, Malan V, Boddaert N, Plouin P, Carter NP, Lyonnet S, Munnich A, et al. Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction. Am J Hum Genet. 2007;80(5):988–93.
doi: 10.1086/515582
pubmed: 17436254
pmcid: 1852736
Mary L, Piton A, Schaefer E, Mattioli F, Nourisson E, Feger C, Redin C, Barth M, El Chehadeh S, Colin E, et al. Disease-causing variants in TCF4 are a frequent cause of intellectual disability: lessons from large-scale sequencing approaches in diagnosis. Eur J Hum Genet. 2018;26(7):996–1006.
doi: 10.1038/s41431-018-0096-4
pubmed: 29695756
pmcid: 6018712
de Winter CF, Baas M, Bijlsma EK, van Heukelingen J, Routledge S, Hennekam RC. Phenotype and natural history in 101 individuals with Pitt-Hopkins syndrome through an internet questionnaire system. Orphanet J Rare Dis. 2016;11:37.
doi: 10.1186/s13023-016-0422-2
pubmed: 27072915
pmcid: 4830011
Zweier C, Peippo MM, Hoyer J, Sousa S, Bottani A, Clayton-Smith J, Reardon W, Saraiva J, Cabral A, Gohring I, et al. Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome). Am J Hum Genet. 2007;80(5):994–1001.
doi: 10.1086/515583
pubmed: 17436255
pmcid: 1852727
Brockschmidt A, Todt U, Ryu S, Hoischen A, Landwehr C, Birnbaum S, Frenck W, Radlwimmer B, Lichter P, Engels H, et al. Severe mental retardation with breathing abnormalities (Pitt-Hopkins syndrome) is caused by haploinsufficiency of the neuronal bHLH transcription factor TCF4. Hum Mol Genet. 2007;16(12):1488–94.
doi: 10.1093/hmg/ddm099
pubmed: 17478476
Dean L. Pitt-Hopkins syndrome. In: medical genetics summaries. edn. Edited by Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ. Bethesda (MD). 2012.
Goodspeed K, Newsom C, Morris MA, Powell C, Evans P, Golla S. Pitt-Hopkins Syndrome: A Review of Current Literature, Clinical Approach, and 23-Patient Case Series. J Child Neurol. 2018;33(3):233–44.
doi: 10.1177/0883073817750490
pubmed: 29318938
pmcid: 5922265
Roos A, Hathazi D, Schara U. Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases. Methods Mol Biol. 2020;2169:197–216.
doi: 10.1007/978-1-0716-0732-9_18
pubmed: 32548831
Gangfuß A, Hentschel A, Heil L, Gonzalez M, Schönecker A, Depienne C, Nishimura A, Zengeler D, Kohlschmidt N, Sickmann A, et al. Proteomic and morphological insights and clinical presentation of two young patients with novel mutations of BVES (POPDC1). Mol Genet Metab. 2022;136(3):226–37.
doi: 10.1016/j.ymgme.2022.05.005
pubmed: 35660068
Liu Y, Ray SK, Yang XQ, Luntz-Leybman V, Chiu IM. A splice variant of E2–2 basic helix-loop-helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an imperfect E-box. J Biol Chem. 1998;273(30):19269–76.
doi: 10.1074/jbc.273.30.19269
pubmed: 9668116
Kremer LS, Danhauser K, Herebian D, Petkovic Ramadza D, Piekutowska-Abramczuk D, Seibt A, Muller-Felber W, Haack TB, Ploski R, Lohmeier K, et al. NAXE Mutations Disrupt the Cellular NAD(P)HX Repair System and Cause a Lethal Neurometabolic Disorder of Early Childhood. Am J Hum Genet. 2016;99(4):894–902.
doi: 10.1016/j.ajhg.2016.07.018
pubmed: 27616477
pmcid: 5065653
Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis. 2007;2:16.
doi: 10.1186/1750-1172-2-16
pubmed: 17397529
pmcid: 1852094
Aramaki S, Yoshida I, Yoshino M, Kondo M, Sato Y, Noda K, Jo R, Okue A, Sai N, Yamashita F. Carbonic anhydrase II deficiency in three unrelated Japanese patients. J Inherit Metab Dis. 1993;16(6):982–90.
doi: 10.1007/BF00711514
pubmed: 8127074
Fang XQ, Kim YS, Lee YM, Lee M, Lim WJ, Yim WJ, Han MW, Lim JH. Polygonum cuspidatum Extract (Pc-Ex) containing emodin suppresses lung cancer-induced cachexia by suppressing TCF4/TWIST1 cComplex-induced PTHrP expression. Nutrients. 2022;5;14(7):1508. Bookshelf ID: NBK66129 10.3390/nu14071508.
Thummarati P, Kino-Oka M. Effect of Co-culturing Fibroblasts in Human Skeletal Muscle Cell Sheet on Angiogenic Cytokine Balance and Angiogenesis. Front Bioeng Biotechnol. 2020;8:578140.
doi: 10.3389/fbioe.2020.578140
pubmed: 33072729
pmcid: 7542332
Sliogeryte K, Gavara N. Vimentin plays a crucial role in fibroblast ageing by regulating biophysical properties and cmigration. Cells. 2019;8(10):1164. https://doi.org/10.3390/cells8101164 .
Kisselbach L, Merges M, Bossie A, Boyd A. CD90 Expression on human primary cells and elimination of contaminating fibroblasts from cell cultures. Cytotechnology. 2009;59(1):31–44.
doi: 10.1007/s10616-009-9190-3
pubmed: 19296231
pmcid: 2677147
Jiang Y, Gruszka D, Zeng C, Swindell WR, Gaskill C, Sorensen C, Brown W, Gangwar RS, Tsoi LC, Webster J, et al. Suppression of TCF4 promotes a ZC3H12A-mediated self-sustaining inflammatory feedback cycle involving IL-17RA/IL-17RE epidermal signaling. JCI Insight. 2024;9(8):e172764. https://doi.org/10.1172/jci.insight.172764 .
Ryu D, Zhang H, Ropelle ER, Sorrentino V, Mazala DA, Mouchiroud L, Marshall PL, Campbell MD, Ali AS, Knowels GM, et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci Transl Med. 2016;8(361):361ra139.
doi: 10.1126/scitranslmed.aaf5504
pubmed: 27798264
pmcid: 5535761
Espinoza F, Carrazana R, Retamal-Fredes E, Ávila D, Papes F, Muotri AR, Ávila A. Tcf4 dysfunction alters dorsal and ventral cortical neurogenesis in Pitt-Hopkins syndrome mouse model showing sexual dimorphism. Biochim Biophys Acta Mol Basis Dis. 2024;1870(5):167178.
doi: 10.1016/j.bbadis.2024.167178
pubmed: 38636614